Natco Pharma- Kothur facility gets 9 observations from USFDA
Read Also: Swiss company Actelion moves US court against Natco Pharma over generic of its patented drug
"At the end of the inspection, the facility received 9 observations, with no repeat observations and mostly procedural in nature," Natco Pharma said in a BSE filing.
The company believes that none of the observations are related to data integrity and that they can be addressed within a short period of time, it added.
Natco Pharma said it will provide due justifications and corrective action plan within next 15 working days to address the USFDA observations.
Read Also: Natco Pharma files ANDA for generic version of Bosentan tablets for oral suspension
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here